tradingkey.logo

Lisata Therapeutics Inc

LSTA

2.330USD

-0.060-2.51%
收盘 09/19, 16:00美东报价延迟15分钟
20.10M总市值
亏损市盈率 TTM

Lisata Therapeutics Inc

2.330

-0.060-2.51%
关于 Lisata Therapeutics Inc 公司
Lisata Therapeutics, Inc. 是一家临床阶段制药公司。该公司致力于发现、开发和商业化用于治疗实体瘤和其他主要疾病的创新疗法。其主要在研产品候选药物 LSTA1 旨在激活一种新型摄取途径,使共同给药或连接的抗癌药物能够渗透到实体瘤中。LSTA1 以肿瘤特异性方式启动这种主动运输系统,导致系统性共同给药的抗癌药物渗透并积聚在肿瘤中,而正常组织不受影响。LSTA1 还具有改变肿瘤微环境 (TME) 的潜力。该公司正在探索 LSTA1 的潜力,以实现多种治疗方式来治疗一系列实体瘤。其 CD34+ 是一种细胞治疗技术,针对一系列疾病,其中包括严重肢体缺血、冠状动脉微血管功能障碍和糖尿病肾病。
公司简介
公司代码LSTA
公司名称Lisata Therapeutics Inc
上市日期Nov 03, 1995
CEODr. David J. Mazzo, Ph.D.
员工数量26
证券类型Ordinary Share
年结日Nov 03
公司地址110 Allen Road
城市BASKING RIDGE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编07920
电话19082292590
网址https://www.lisata.com/
公司代码LSTA
上市日期Nov 03, 1995
CEODr. David J. Mazzo, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. David J. Mazzo, Ph.D.
Dr. David J. Mazzo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
264.69K
+3.26%
Dr. Kristen K. Buck, M.D.
Dr. Kristen K. Buck, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
79.79K
--
Dr. Mohammad Azab, M.D.
Dr. Mohammad Azab, M.D.
Independent Director
Independent Director
52.28K
+23.92%
Mr. Steven Mark (Steve) Klosk, J.D.
Mr. Steven Mark (Steve) Klosk, J.D.
Independent Director
Independent Director
49.57K
+8.05%
Dr. Gregory B. Brown, M.D.
Dr. Gregory B. Brown, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
49.41K
+8.07%
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
39.48K
+10.31%
Mr. Tariq Imam
Mr. Tariq Imam
Senior Vice President, Business Development and Operations and General Counsel
Senior Vice President, Business Development and Operations and General Counsel
24.58K
--
Mr. James Nisco
Mr. James Nisco
Senior Vice President - Finance and Treasury, Chief Accounting Officer
Senior Vice President - Finance and Treasury, Chief Accounting Officer
23.49K
--
Mr. John D. Menditto
Mr. John D. Menditto
Vice President - Investor Relations & Corporate Communications
Vice President - Investor Relations & Corporate Communications
--
--
Ms. Cynthia L. Flowers
Ms. Cynthia L. Flowers
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. David J. Mazzo, Ph.D.
Dr. David J. Mazzo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
264.69K
+3.26%
Dr. Kristen K. Buck, M.D.
Dr. Kristen K. Buck, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
79.79K
--
Dr. Mohammad Azab, M.D.
Dr. Mohammad Azab, M.D.
Independent Director
Independent Director
52.28K
+23.92%
Mr. Steven Mark (Steve) Klosk, J.D.
Mr. Steven Mark (Steve) Klosk, J.D.
Independent Director
Independent Director
49.57K
+8.05%
Dr. Gregory B. Brown, M.D.
Dr. Gregory B. Brown, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
49.41K
+8.07%
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
39.48K
+10.31%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月17日 周日
更新时间: 8月17日 周日
持股股东
股东类型
持股股东
持股股东
占比
Ruoslahti (Erkki)
12.60%
Mazzo (David J)
3.02%
The Vanguard Group, Inc.
2.90%
BML Capital Management LLC
2.40%
Renaissance Technologies LLC
1.17%
其他
77.91%
持股股东
持股股东
占比
Ruoslahti (Erkki)
12.60%
Mazzo (David J)
3.02%
The Vanguard Group, Inc.
2.90%
BML Capital Management LLC
2.40%
Renaissance Technologies LLC
1.17%
其他
77.91%
股东类型
持股股东
占比
Individual Investor
19.82%
Investment Advisor
6.35%
Investment Advisor/Hedge Fund
1.27%
Hedge Fund
1.19%
Research Firm
0.12%
其他
71.24%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
48
2.52M
29.29%
-66.93K
2025Q1
50
2.57M
30.49%
+155.41K
2024Q4
48
2.39M
27.90%
-46.00K
2024Q3
48
2.33M
27.50%
-84.74K
2024Q2
59
2.31M
27.35%
-158.27K
2024Q1
60
2.32M
28.57%
+1.21M
2023Q4
63
2.13M
26.53%
+1.00M
2023Q3
72
2.18M
28.45%
+396.20K
2023Q2
72
2.18M
28.62%
+428.28K
2023Q1
74
1.03M
14.30%
-575.31K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Ruoslahti (Erkki)
1.10M
12.83%
-78.14K
-6.62%
Apr 17, 2025
Mazzo (David J)
264.69K
3.08%
+8.35K
+3.26%
Apr 17, 2025
The Vanguard Group, Inc.
254.18K
2.96%
+67.82K
+36.39%
Mar 31, 2025
BML Capital Management LLC
216.85K
2.52%
-67.82K
-23.82%
Mar 31, 2025
Renaissance Technologies LLC
102.72K
1.19%
+1.40K
+1.38%
Mar 31, 2025
Buck (Kristen K)
79.79K
0.93%
--
--
Apr 17, 2025
Geode Capital Management, L.L.C.
60.53K
0.7%
+4.63K
+8.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
54.86K
0.64%
-1.16K
-2.06%
Mar 31, 2025
Azab (Mohammad)
52.28K
0.61%
+10.09K
+23.92%
Apr 17, 2025
Klosk (Steven Mark)
49.57K
0.58%
+3.69K
+8.05%
Apr 17, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%
分红派息
近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Sep 14, 2022
Merger
15→1
Sep 14, 2022
Merger
15→1
Sep 14, 2022
Merger
15→1
Sep 14, 2022
Merger
15→1
公告日期
类型
比率
Sep 14, 2022
Merger
15→1
Sep 14, 2022
Merger
15→1
Sep 14, 2022
Merger
15→1
Sep 14, 2022
Merger
15→1
KeyAI